risperidone has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christian, BT; Mantil, J; Mukherjee, J; Narayanan, TK; Shi, B | 1 |
| Bertolino, A; Dipasquale, O; Dukart, J; Hawkins, PCT; Mehta, MA; Pergola, G; Rizzo, G; Sambataro, F; Selvaggi, P; Turkheimer, F; Veronese, M; Williams, SCR; Zelaya, F | 1 |
1 trial(s) available for risperidone and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Cerebrovascular Circulation; Cross-Over Studies; Dopamine D2 Receptor Antagonists; Double-Blind Method; Fluorine Radioisotopes; Haloperidol; Healthy Volunteers; Humans; Olanzapine; Positron-Emission Tomography; Receptors, Dopamine D2; Risperidone; RNA, Messenger; Spin Labels | 2019 |
1 other study(ies) available for risperidone and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzamides; Brain; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Haloperidol; Macaca mulatta; Male; Neostriatum; Pyrrolidines; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone; Tomography, Emission-Computed | 2001 |